Loading...
•
Dec 31, 2024
Baxter Q4 2024 Earnings Report
Baxter reported strong Q4 2024 results with revenue exceeding guidance, driven by robust performance in Medical Products & Therapies and Pharmaceuticals.
Key Takeaways
Baxter's Q4 2024 revenue totaled $2.75 billion, up 1% year-over-year, exceeding expectations. Adjusted EPS, including discontinued operations, was $0.77, surpassing prior guidance. Strong sales in Pharmaceuticals and Medical Products & Therapies offset weaker results in Healthcare Systems & Technologies. Net income from continuing operations was negative due to special items, including goodwill impairments and restructuring costs.
Revenue reached $2.75 billion, exceeding prior guidance with 1% YoY growth.
Adjusted EPS of $0.77 outperformed the previous guidance range of $0.77-$0.81.
Pharmaceuticals segment saw high single-digit growth, led by injectables and drug compounding.
Hurricane Helene's impact was lower than anticipated, aiding operational performance.
Baxter
Baxter
Baxter Revenue by Segment
Baxter Revenue by Geographic Location
Revenue by Segment
Other Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Baxter expects continued revenue growth in 2025, with sales projected to increase 5-6% on a reported basis. Adjusted EPS is expected to be between $2.45 and $2.55 for FY 2025.
Positive Outlook
- Projected 5-6% revenue growth in FY 2025.
- Strong momentum in Pharmaceuticals and Medical Products & Therapies segments.
- Operational improvements post-Kidney Care divestiture.
- Lower-than-expected Hurricane Helene impact.
- Focus on debt repayment and cash flow improvement.
Challenges Ahead
- Continued challenges in Healthcare Systems & Technologies segment.
- Supply constraints impacting select product lines.
- Competitive pricing pressures in key markets.
- Macroeconomic uncertainty affecting global healthcare demand.
- Potential foreign exchange headwinds in international markets.